+

DK0664708T3 - Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe - Google Patents

Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe

Info

Publication number
DK0664708T3
DK0664708T3 DK93907581T DK93907581T DK0664708T3 DK 0664708 T3 DK0664708 T3 DK 0664708T3 DK 93907581 T DK93907581 T DK 93907581T DK 93907581 T DK93907581 T DK 93907581T DK 0664708 T3 DK0664708 T3 DK 0664708T3
Authority
DK
Denmark
Prior art keywords
phase
spec
combination therapy
treating cancer
halomethylidene
Prior art date
Application number
DK93907581T
Other languages
Danish (da)
English (en)
Inventor
Sai P Sunkara
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of DK0664708T3 publication Critical patent/DK0664708T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK93907581T 1992-04-10 1993-03-15 Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe DK0664708T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10
PCT/US1993/002490 WO1993020825A1 (fr) 1992-04-10 1993-03-15 Procede de traitement du cancer par association therapeutique de derives de 2'-halomethylidene et d'un agent antineoplasique specifique par rapport a la phase s ou m

Publications (1)

Publication Number Publication Date
DK0664708T3 true DK0664708T3 (da) 1998-11-02

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93907581T DK0664708T3 (da) 1992-04-10 1993-03-15 Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe

Country Status (17)

Country Link
US (2) US20040102461A1 (fr)
EP (1) EP0664708B1 (fr)
JP (1) JP3713668B2 (fr)
KR (1) KR100258668B1 (fr)
AT (1) ATE170077T1 (fr)
AU (1) AU667527B2 (fr)
CA (1) CA2117891C (fr)
DE (1) DE69320646T2 (fr)
DK (1) DK0664708T3 (fr)
ES (1) ES2123642T3 (fr)
HU (1) HU219476B (fr)
IL (1) IL105329A (fr)
MX (1) MX9302038A (fr)
NZ (1) NZ251211A (fr)
TW (1) TW362971B (fr)
WO (1) WO1993020825A1 (fr)
ZA (1) ZA932455B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001638A1 (fr) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Procede de traitement du stade neoplasique d'une affection par therapie associant des derives de 2'-fluorometylidene et une radiotherapie ou chimiotherapie
US5811408A (en) * 1994-07-12 1998-09-22 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
EP1009407B1 (fr) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie
CA2326004A1 (fr) 2000-11-02 2002-05-02 Richard E. Jones Methodes de traitement de troubles cellulaires proliferatifs
CN1646534A (zh) * 2002-02-14 2005-07-27 法玛塞特有限公司 修饰的氟化核苷类似物
WO2004042081A1 (fr) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Haplotypes specifiques du gene mdr1 et leur utilisation en diagnostic et en therapie
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
WO2012012764A1 (fr) 2010-07-23 2012-01-26 Demerx, Inc. Compositions de noribogaïne
EP2481740B1 (fr) 2011-01-26 2015-11-04 DemeRx, Inc. Procédés et compositions pour préparer de la noribogaïne à partir de voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
JP2015500833A (ja) 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
SI2794627T1 (sl) 2011-12-22 2019-02-28 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9783535B2 (en) 2012-12-20 2017-10-10 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2015195673A2 (fr) 2014-06-18 2015-12-23 Demerx, Inc. Dérivés d'indole et de benzofurane halogénés d'isoquinuclidène et procédés pour leur préparation.

Also Published As

Publication number Publication date
EP0664708A1 (fr) 1995-08-02
CA2117891C (fr) 1998-07-07
HUT71224A (en) 1995-11-28
KR950700749A (ko) 1995-02-20
DE69320646D1 (de) 1998-10-01
DE69320646T2 (de) 1999-01-14
HU219476B (hu) 2001-04-28
NZ251211A (en) 1997-05-26
ZA932455B (en) 1993-10-20
ATE170077T1 (de) 1998-09-15
ES2123642T3 (es) 1999-01-16
JPH07505653A (ja) 1995-06-22
KR100258668B1 (ko) 2000-07-01
US20040102461A1 (en) 2004-05-27
HU9402914D0 (en) 1995-01-30
WO1993020825A1 (fr) 1993-10-28
AU3813193A (en) 1993-11-18
JP3713668B2 (ja) 2005-11-09
EP0664708A4 (fr) 1995-04-24
CA2117891A1 (fr) 1993-10-28
US20050032738A1 (en) 2005-02-10
IL105329A (en) 1998-06-15
AU667527B2 (en) 1996-03-28
TW362971B (en) 1999-07-01
EP0664708B1 (fr) 1998-08-26
IL105329A0 (en) 1993-08-18
MX9302038A (es) 1993-10-01

Similar Documents

Publication Publication Date Title
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
BR9306619A (pt) Glicosídeos esteroidais para o tratamento da hipercolesterolemia
DK0513702T3 (da) Melatoninderivater til anvendelse til behandling af søvnlidelser og til præ-anæstetisk medicinering
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
DK95091D0 (da) Anvendelse af acetyl-d-carnitin ved terapeutisk behandling af glaucoma
FI910413A7 (fi) Tooppiset valmisteet ihmisen kynsien hoitamiseksi
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
IL101245A0 (en) Pharmaceutical compositions for the treatment of prostatic cancer
NO931413D0 (no) Fremgangsmaater og preparater for behandling av celleproliferasjonssykdommer
ITMI910456A0 (it) Composizione farmaceutica per il trattamento della cataratta
FI911788A7 (fi) Difluoriglutamiinihapon konjugaatteja folaattien ja antifolaattien kanssa uudiskasvusairauksien hoitoa varten
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
FI911778A7 (fi) Difluoriglutamiinihappo-konjugaatit folaattien ja antifolaattien kanssa neoplastisten sairauksien hoitoon
ATE149840T1 (de) Behandlung von leberkrebs
FI911533A7 (fi) Bentsoksatsiini-johdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö sairauksien hoitamiseen tai ennalta ehkäisemiseksi
DK0572549T3 (da) Behandling af ikke-småcellet lungecarcinom
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
IT1243734B (it) Composizione per uso terapeutico e/o cosmetico per il trattamento di disturbi circolatori e per trattamenti di medicina estetica
DK1023314T3 (da) Galdesyredsalte af metaller med fysiologisk virkning og anvendelsen deraf ved terapi
BR9708037A (pt) Método para o tratamento de abuso de substância
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten
NO952194D0 (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载